ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, a VEGFR inhibitor axitinib was recently identified as a potent and selective BCR-ABL(T315I) inhibitor (Pemovska et al., 2015), and it is currently undergoing a clinical trial for CML (NCT02782403).